Scott C. Neils - 15 Nov 2025 Form 4 Insider Report for Xtant Medical Holdings, Inc. (XTNT)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
18 Nov 2025, 16:26:10 UTC
Prior SEC filing
19 Aug 2025
Next SEC filing
16 Jan 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Amy Culbert, attorney-in-fact

Key filing fact

Scott C. Neils filed Form 4 for Xtant Medical Holdings, Inc. (XTNT) on 18 Nov 2025.

Key facts

  • This page summarizes Scott C. Neils's Form 4 filing for Xtant Medical Holdings, Inc. (XTNT).
  • 2 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 18 Nov 2025, 16:26.

Change

  • Previous filing in this sequence was filed on 19 Aug 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001902610 Primary reporting owner

Neils Scott C

Relationship
CFO and Assistant Secretary
Address
C/O XTANT MEDICAL HOLDINGS, INC., 664 CRUISER LANE, BELGRADE
Signature
/s/ Amy Culbert, attorney-in-fact
Signature date
18 Nov 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

XTNT transaction

Common Stock

Award

Transaction value
$0
Shares
+263,291
Change %
+45%
Price
$0.000000
Shares after
851,465
Date
15 Nov 2025
Ownership
Direct
Footnotes
F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

XTNT transaction Derivative

Performance Stock Units (PSUs)

Award

Transaction value
$0
Shares
+526,582
Change %
Price
$0.000000
Shares after
526,582
Date
15 Nov 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
526,582
Exercise price
Footnotes
F3, F4
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

These shares will vest with respect to 65,822 shares on each of November 15, 2026, November 15, 2027, and November 15, 2028, and with respect to 65,825 shares on November 5, 2029 pursuant to a deferred stock unit (DSU) award granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining an employee of Xtant through the applicable vesting date. The settlement of the vested shares underlying the DSU award has been deferred and will occur at a later date pursuant to the terms of the DSU award agreement. Each DSU represents a contingent right to receive one share of the Issuer's common stock.

Footnote F2

Includes an aggregate of 498,914 shares issuable upon vesting and settlement of restricted stock unit (RSU) awards or DSU awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan and 85,220 shares issuable upon vesting and settlement of RSU awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, in each case conditioned upon the Reporting Person remaining an employee of Xtant through the respective vesting dates.

Footnote F3

Each PSU represents a contingent right to receive one share of the Issuer's common stock. The PSUs will vest and become earned in one-third increments based on the achievement of specified stock price performance goals during a three-year performance period and subject to additional service-based vesting conditions.

Footnote F4

Represents the maximum number of shares that may be issued pursuant to the PSUs, which is 200% of the target number of shares (263,291).

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .